Role of biological heterogeneity in recurrent and metastatic breast cancer

Close metadata

Recommended articles:

Vestibular rehabilitation for peripheral vestibular hypofunction: an interdisciplinary consensus. Russian Bulletin of Otorhinolaryngology. 2024;(1):52-63

The Russian consensus on the treatment of intrahepatic cholangiocarcinoma. Pirogov Russian Journal of Surgery. 2024;(10):7-20

Cryoballoon ablation combined with antiarrhythmic therapy for atrial fibrillation in patients with cardiovascular comorbidities. Russian Journal of Cardiology and Cardiovascular Surgery. 2024;(6):670-676

Breast cancer (BC) is a heterogeneous tumor, the biological characteristics of which vary with its growth and progression. Information on key tumor receptors (ER, PR, HER2, and Ki-67) is the basis for individualizing the diagnostic and treatment algorithm at all BC stages; however, the feasibility of biopsy of distant metastases and the re-testing of the biological subtype of BC in its suspected progression are being actively discussed in clinical practice. This review presents an update on the features of metastasis in different biological BC subtypes and assesses the clinical and prognostic role of biopsy of distant metastases in the lung, bones, liver, and brain. It shows the frequency of discordance in receptor status between primary and recurrent tumors at different sites of metastases, as well as the impact of changes in receptor status on survival rates in different biological BC subtypes. The relevance of performing biopsies in BC progression is shown to be beyond question, because it makes it possible to confirm the fact that the disease progresses, to re-test the biological subtype of recurrent BC, and to find new targets that allow the most effective drug treatment regimens to be used.

Keywords:

recurrent and metastatic breast cancer

heterogeneity of breast cancer

discordance in receptor status of tumor

features of metastasis in different biological breast cancer subtypes

drug therapy

personalized approach to breast cancer therapy

Authors:

Kolyadina I.V.

Russian Medical Academy of Continuing Professional Education, Moscow, Russia

Andreeva Yu.Yu.

Russian Medical Academy of Continuing Professional Education, Ministry of Health of Russia

SPIN RSCI: 6504-2551
Scopus AuthorID: 8656328100
ORCID: 0000-0003-4749-6608

Frank G.A.

Moskovskiĭ nauchno-issledovatel'skiĭ onkologicheskiĭ institut im. P.A. Gertsena Rosmedtekhnologiĭ, Moskva

ORCID: 0000-0002-3719-5388

Poddubnaia I.V.

Kafedra onkologii RMAPO, Moskva

List of references:

GLOBOCAN 2012. Available at: https://globocan.iarc.fr/Default.aspx
Kaprin AD, Starinskii VV, Petrova GV, eds. Zlokachestvennye novoobrazovaniya v Rossii v 2016 (zabolevaemost’ i smertnost’). Moscow: MNIOI im. P.A. Gertsena — filial FGBU «NMITs radiologii» Minzdrava Rossii; 2018. (In Russ.) Available at: https://www.oncology.ru/service/statistics/malignant_tumors/2016.pdf
Zhang Y, Schroeder BE, Jerevall PL, Ly A, Nolan H, Schnabel CA, Sgroi DC. A novel breast cancer index for prediction of distant recurrence in HR+ early-stage breast cancer with One to three positive nodes. Clin Cancer Res. 2017;23(23):7217-7224. https://doi.org/10.1158/1078-0432.CCR-17-1688
Pan H, Gray R, Braybrooke J, Davies C, Taylor C, McGale P, Peto R, Pritchard KI, Bergh J, Dowsett M, Hayes DF; EBCTCG. 20-year risks of breast-cancer recurrence after stopping endocrine therapy at 5 years. N Engl J Med. 2017;377(19):1836-1846. https://doi.org/10.1056/NEJMoa1701830
Kolyadina IV, Poddubnaya I, Pavlikova O, Komov D, Andreeva Yu, Frank G. Features of p53 expression in residual tumors in Russian women after neoadjuvant chemotherapy of breast cancer stage T1-3N0-1. J Clin Oncol. 2017;35(15,Suppl.):e12121. https://doi.org/10.1200/JCO.2017.35.15_suppl.e12121
Kolyadina IV, Poddubnaya I, Van De Velde CJH, Kuppen PJK, Bastiaannet E, Davydov M, Kotov D, Frank G. The prognostic value of the immune profile of breast cancer stage I in Russian and Dutch women. J Clin Oncol. 2016;34(15:Suppl.):e23108. https://doi.org/10.1200/JCO.2016.34.15_suppl.e23108
Moskvina LV, Andreeva YuYu, Zavalishina LE, Ilatovskaya M, Frank G. Breast cancer intratumoral heterogeneity in routine practice. Virchows Archiv. 2016;469(Suppl.1):S56. https://www.springer.com/medicine/pathology/journal/428
Kolyadina IV, Poddubnaya IV, Frank GA, Komov DV, Karseladze AI, Ermilova VD, Vishnevskaya YV. Stage I breast cancer heterogeneity: biological and predictive value. Malignant Tumors. 2015;1:31-40.
Wu Q, Li J, Zhu S, Wu J, Chen C, Liu Q, Wei W, Zhang Y, Sun S. Breast cancer subtypes predict the preferential site of distant metastases: a SEER based study. Oncotarget. 2017;8(17):27990-27996. https://doi.org/10.18632/oncotarget.15856
Wu X, Baig A, Kasymjanova G, Kafi K, Holcroft C, Mekouar H, Carbonneau A, Bahoric B, Sultanem K, Muanza T. Pattern of local recurrence and distant metastasis in breast cancer by molecular subtype. Cureus. 2016;8(12):e924. https://doi.org/10.7759/cureus.924
Kaplan M, Arslan U, Isıkdogan A, Dane F, Oksuzoglu B, Inanc M, et al. Biological subtypes and distant relapse patern in breast cancer paients afer curaive surgery. Study of Anatolian Society of Medical Oncology. Breast Care (Basel). 2016;11(4):248-252. https://doi.org/10.1056/NEJMoa1701830
Qu Q, Zong Y, Fei XC, Chen XS, Xu C, Lou GY, Shen KW. The importance of biopsy in clinically diagnosed metastatic lesions in patients with breast cancer. World J Surg Oncol. 2014;12:93. https://doi.org/10.1186/1477-7819-12-93
Dieci MV, Barbieri E, Piacentini F, Ficarra G, Bettelli S, Dominici M, Conte PF, Guarneri V. Discordance in receptor status between primary and recurrent breast cancer has a prognostic impact: a single-institution analysis. Ann Oncol. 2013;24(1):101-108. https://doi.org/10.1093/annonc/mds248
Thompson AM, Jordan LB, Quinlan P, Anderson E, Skene A, Dewar JA, Purdie CA; Breast Recurrence in Tissues Study Group. Prospective comparison of switches in biomarker status between primary and recurrent breast cancer: the Breast Recurrence In Tissues Study (BRITS). Breast Cancer Res. 2010;12(6):R92. https://doi.org/10.1186/bcr2771
Erdem GU, Altundag K, Ozdemir NY, Sahin S, Demirci NS, Karatas F, Bozkaya Y, Aytekin A, Tasdemir V, Aslan AC, Sever AR, Zengin N. Comparative study of receptor discordance between primary and corresponding metastatic lesions in breast cancer. J BUON. 2017;22(2):365-376.
Lower EE, Khan S, Kennedy D, Baughman RP. Discordance of the estrogen receptor and HER-2/neu in breast cancer from primary lesion to first and second metastatic site. Breast Cancer (Dove Med Press). 2017;9:515-520. https://doi.org/10.2147/BCTT.S137709
Lindström LS, Karlsson E, Wilking UM, Johansson U, Hartman J, Lidbrink EK, Hatschek T, Skoog L, Bergh J. Clinically used breast cancer markers such as estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 are unstable throughout tumor progression. J Clin Oncol. 2012;30(21):2601-2608. https://doi.org/10.1200/JCO.2011.37.2482
Shin HC, Han W, Moon HG, Im SA, Moon WK, Park IA, Park SJ, Noh DY. Discordant ER, PR, and HER2 status between primary and metastatic breast cancer as prognostic factor. J Clin Oncol. 2013;31(15,Suppl.):abstr.1039. https://doi.org/10.1200/jco.2013.31.15_suppl.1039
Ilgun S, Sarsenov D, Erdogan Z, Ordu C, Celebi F, Nur Pilanci K, Ozturk A, Selamoglu D, Alco G, Aktepe F, Eralp Y, Tuzlali S, Ozmen V. Receptor discordance rate and its effects on survival in primary and recurrent breast cancer patients. J BUON. 2016;21(6):1425-1432.
Shachar SS, Mashiach T, Fried G, Drumea K, Shafran N, Muss HB, Bar-Sela G. Biopsy of breast cancer metastases: patient characteristics and survival. BMC Cancer. 2017;17(1):7. https://doi.org/10.1186/s12885-016-3014-6
Gupta S, Wallace MJ, Cardella JF, Kundu S, Miller DL, Rose SC; Society of Interventional Radiology Standards of Practice Committee. Quality improvement guidelines for percutaneous needle biopsy. J Vasc Interv Radiol. 2010;21(7):969-975.
Aurilio G, Monfardini L, Rizzo S, Sciandivasci A, Preda L, Bagnardi V, Disalvatore D, Pruneri G, Munzone E, Della Vigna P, Renne G, Bellomi M, Curigliano G, Goldhirsch A, Nolè F. Discordant hormone receptor and human epidermal growth factor receptor 2 status in bone metastases compared to primary breast cancer. Acta Oncol. 2013;52(8):1649-1656. https://doi.org/10.3109:0284186X.2012.754990
Matsuura K, Itamoto T, Noma M, Ohara M, Akimoto E, Doi M, Nishisaka T, Arihiro K, Kadoya T, Okada M. Signifcance of lung biopsy for the defniive diagnosis of lung nodules in breast cancer paients. Mol Clin Oncol. 2018;8(2):250-256. https://doi.org/10.3892:mco.2017.1511
Liu J, Deng H, Jia W, Zeng Y, Rao N, Li S, Jin L, Wu J, Song E, Su F. Comparison of ER/PR and HER2 statuses in primary and paired liver metastatic sites of breast carcinoma in patients with or without treatment. J Cancer Res Clin Oncol. 2012;138(5):837-842.
Curigliano G, Bagnardi V, Viale G, Fumagalli L, Rotmensz N, Aurilio G, Locatelli M, Pruneri G, Giudici S, Bellomi M, Della Vigna P, Monfardini L, Orsi F, Nolè F, Munzone E, Goldhirsch A. Should liver metastases of breast cancer be biopsied to improve treatment choice? Ann Oncol. 2011;22(10):2227-2233. https://doi.org/10.1093:annonc:mdq751
Botteri E, Disalvatore D, Curigliano G, Brollo J, Bagnardi V, Viale G, Orsi F, Goldhirsch A, Rotmensz N. Biopsy of liver metastasis for women with breast cancer: impact on survival. Breast. 2012;21(3):284-288. https://doi.org/10.1016/j.breast.2011.12.014
Timmer M, Werner JM, Röhn G, Ortmann M, Blau T, Cramer C, Stavrinou P, Krischek B, Mallman P, Goldbrunner R. Discordance and conversion rates of progesterone-, estrogen-, and HER2/neu-receptor status in primary breast cancer and brain metastasis mainly triggered by hormone therapy. Anticancer Res. 2017;37(9):4859-4865.
Jung J, Lee SH, Park M, Youn JH, Shin SH, Gwak HS, Yoo H. Discordances in ER, PR, and HER2 between primary breast cancer and brain metastasis. J Neurooncol. 2018;137(2):295-302. https://doi.org/10.1007/s11060-017-2717-0

Close metadata